stockrow
Saturday 7 November 2026
Export MCRB’s income statement to Excel — free account
Seres Therapeutics, Inc.
MCRB Healthcare Biotechnology
Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- −273.6%
- Free cash flow
- −576.7%
Quarter to September 2026, against a year earlier
1.98
0.11
−5.26%
Follow MCRB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
19.64% | (121.87%) | (66.57%) | (144.35%) | |
| 4.10% | (33.29%) | (18.31%) | (44.85%) | ||
ROIC |
0.00% | 0.00% | (277.30%) | (1,267.77%) | |
Return on Tangible Assets |
15.11% | (242.41%) | (79.90%) | (284.06%) | |
Average Days of Receivables |
128.11 | 55.91 | 4,899.10 | 2,178.49 | |
Free Cash Flow per Share |
0.12 | (4.40) | (5.28) | (6.38) | |
Free Cash Flow |
1.08 | (42.15) | (51.25) | (63.70) | |
Capital Expenditures |
(0.04) | — | 0.01 | 0.24 | |
| Other line items | |||||
Cash ROIC |
1.19% | (74.83%) | (102.24%) | (163.81%) | |
Accounts Receivable Turnover |
1.14 | 1.02 | 0.14 | 0.32 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,330.62% | 3,315.84% | 2,476.69% | 1,864.09% | |
Selling, General and Administrative Expense of Revenue |
2,658.25% | 2,323.34% | 1,707.17% | 1,323.20% | |
Share Based Compensation of Revenue |
735.91% | 643.46% | 487.84% | 402.96% | |
Operating CF/Net income |
0.20 | 0.90 | 2.28 | 1.36 | |
Depreciation/Fixed assets |
0.54 | 0.56 | 0.59 | 0.96 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.08 | |
Revenue per Share |
0.17 | 0.16 | 0.19 | 0.21 | |
Operating CF per Share |
0.13 | (4.40) | (5.28) | (6.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.02 | |
Capex to Sales |
0.03 | 0.00 | 0.00 | (0.11) |
Columns are period end dates · fundamentals updated 6 Nov 2026